Showing results (371-380 of 760) with videos related to

Sort By:
Pageof 76
Molecular Cancer Therapeutics|June 19, 2007
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cellsTanyel Kiziltepe, Teru Hideshima, Laurence Catley, et al.
British Journal of Haematology|September 12, 2008
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myelomaSundar Jagannath, Bart Barlogie, James R Berenson, et al.
Cells|November 30, 2019
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with IsatuximabThomas G Martin, Kathryn Corzo, Marielle Chiron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2011
Significant biological role of sp1 transactivation in multiple myelomaMariateresa Fulciniti, Samir Amin, Puru Nanjappa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma modelPaola Neri, Shaji Kumar, Maria Teresa Fulciniti, et al.
Blood|October 25, 2008
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERKYutaka Okawa, Teru Hideshima, Paul Steed, et al.
Blood|December 14, 2002
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arraysDharminder Chauhan, Guilan Li, Daniel Auclair, et al.
Blood|July 2, 2002
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myelomaChristian Brander, Noopur Raje, Paula G O'Connor, et al.
Cancer Research|July 5, 2005
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myelomaYu-Tzu Tai, Xianfeng Li, Xia Tong, et al.
Blood Cancer Journal|August 16, 2022
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiationHailin Chen, Tengteng Yu, Liang Lin, et al.
Pageof 76